Prognostic Value of Tumor Associated Macrophage Markers CD163 and CD68 Immunohistochemistry in Classical Hodgkin Lymphoma.

Abstract

Tumor associated macrophages have been implicated in the pathogenesis of classical Hodgkin's lymphoma and have been suggested to have a negative impact on outcome. The aim of this study is to determine the expression and the prognostic impact of CD163 and CD68 markers of the tumor associated macrophages, in the initial positively infiltrated bone marrow biopsy specimens of our subjects by immunohistochemistry and to corre¬late their expression with other clinical and laboratory prognostic factors. This study was conducted on fifty-one patients with de novo classical Hodgkin's lymphoma, presenting to the Clinical Pathology Department at the National Cancer Institute, Cairo University. CD163 and CD68 were detected in the initial bone marrow biopsy specimens from our subjects by immunohistochemistry. The present study included 51 patients with CHL. They comprised 24 males (47.1%) and 27 females (52.9%) with an age of 32.9 ± 14.5 years. After treatment, 33 patients (64.7%) achieved complete remission while 18 patients (35.3%) failed. Comparison between patients with CR and patients without revealed significantly lower CD68 expression [median (IQR): 30.0 (15.0 - 47.5%) versus 55.0 (43.8 - 55.0%), p = 0.003] and CD163 expression [25.0 (10.0 - 37.5%) versus 45.0 (0.35 - 55.0%)] in CR patients. Binary logistic regression analysis identified CD68 and CD163 expressions as significant predictors of CR in univariate and multivariate analyses. The expressions of both tumor-associated markers, CD68 and CD163, are significant predictors of CR in patients with CHL.